MedImmune FluMist “complete response”
Executive Summary
MedImmune issues response to third "complete response" letter for intranasal flu vaccine FluMist Feb. 7. FDA outlined five questions in its Jan. 29 letter: one labeling clarification; three technical clarifications; and a fifth question on postmarketing studies. FluMist, which is co-developed with Wyeth, has been under review since October 2000. FDA's Vaccine & Related Biological Products Advisory Committee recommended approval for healthy patients between five and 49 years of age (1"The Pink Sheet" Dec. 23, 2002, p. 23). MedImmune expects a second quarter approval...
You may also be interested in...
MedImmune FluMist Capacity Could Reach 20 Mil. Doses For 2004 Season
MedImmune expects up to a five-fold increase in FluMist vaccine supply for the 2004 influenza season
Wyeth FluMist Draft Label Will Be Reviewed By CDC Cmte. To Speed Coverage
Wyeth has obtained permission from FDA to provide draft labeling for its intranasal flu vaccine FluMist to CDC's Advisory Committee on Immunization Practices in order to speed a coverage decision once the product is approved
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
MedImmune should conduct head-to-head comparisons of its live intranasal flu vaccine FluMist and the marketed trivalent inactivated vaccine, FDA's Vaccine & Related Biological Drug Products Advisory Committee suggested Dec. 17